Simponi Aria (golimumab) from Janssen Pharmaceutical Company of Johnson & Johnson is the first and only fully human anti-tumor necrosis factor (TNF) biologic approved by the FDA to include language in its product label stating that the treatment results in improvement in fatigue for adult patients with active PsA and for adult patients with moderately to severely active RA.

The effect of Simponi Aria on fatigue was measured by the Functional Assessment of Chronic Illness Therapy – Fatigue (FACIT-F), which tracks self-reported tiredness, weakness, and difficulty conducting usual activities due to fatigue.  

Simponi Aria joins Janssen’s Tremfya ® (guselkumab) as the only products in PsA to have improvement in fatigue, as measured by FACIT-F, included in their respective labels.